Shaping a future free from Alzheimer's disease
Goals scored by the Wisconsin men’s and women’s hockey teams this year will not only help them win more games, but will also help raise money to support important Alzheimer’s research and treatment at the University of Wisconsin.
Research participants have begun volunteering for brain scans at the University of Wisconsin School of Medicine and Public Health in Madison for a national study on Alzheimer’s disease and related dementias.
The research team of Maria Mora Pinzon, MD, MS, FACPM, is collaborating with a research team from the Milwaukee-based United Community Center (UCC) and dementia experts from UCC Latino Geriatric Center to develop a new educational curriculum for University of Wisconsin-Madison medical students.
Congratulations Dr. Walaszek!
The Amazing Grace Chorus, a community program hosted by the Wisconsin Alzheimer’s Institute Regional Milwaukee Office, welcomes new members to join the new program.
This toolkit provides a guide with illustrative examples to assist preventive medicine physicians and related partners to educate patients on Alzheimer’s disease and related dementias, reduce risk factors related to dementia.
University of Wisconsin–Madison Alzheimer’s disease research programs are featured in the August 2024 issue of Madison Magazine.
The Initiative to End Alzheimer’s (IEA) Innovation fund’s goal is to advance promising new ideas in UW–Madison Alzheimer’s Disease (AD) research and programming, enhance resources available to researchers, program leads and staff and respond to innovative and emerging needs of this area of medicine. The IEA Innovation Fund aims to be a key driver of novel ideas and entrepreneurial energy for both the Wisconsin ADRC and WAI.
On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.
Wisconsin Alzheimer’s Institute staff and leaders helped lead development of state plan